ReviewNature reviews. Cancer2023
Bacteria in cancer initiation, promotion and progression.
Review in Nature reviews. Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07676461 (Atlas of the Oral, Fecal and Intratumoral Microbiome of Colombian Patients With Advanced Solid Tumors Candidates for First-Line Immunotherapy - Initial Phase of a Project With Latin American Projection), which is not on this map. Cited by 212 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Atlas of the Oral, Fecal and Intratumoral Microbiome of Colombian Patients With Advanced Solid Tumors Candidates for First-Line Immunotherapy - Initial Phase of a Project With Latin American Projection
Who cites it
212 citing papers in PubMed, 3 syntheses or guidelines pooled it, 287 citations in OpenAlex.
- The impact of bariatric surgery on gut microbiota: a bibliometric analysis of research trends and scientific contributions.Frontiers in microbiology · 2025Pooled it
- Gut microbiota and gastrointestinal tumors: insights from a bibliometric analysis.Frontiers in microbiology · 2025Pooled it
- Guideline for designing microbiome studies in neoplastic diseases.GeroScience · 2024Guideline
- Effect of a Novel Food Rich in Miraculin on the Intestinal Microbiome of Malnourished Patients with Cancer and Dysgeusia.Nutrients · 2025Trial
- Gut microbiota and diet in colorectal cancer: Converging determinants of carcinogenesis.Gut microbes · 2026Review
- Shaping the future of early-onset colorectal cancer prevention.Nature reviews. Cancer · 2026Review
- Systemic health impact of cancer-associated extracellular vesicles and particles.Nature reviews. Cancer · 2026Review
- Decoding the cancer microbiome: multi-omics, AI, and translational opportunities.Genome biology · 2026Review
- Molecular pathways linking the gut microbiome to antitumor immunity.Trends in microbiology · 2026Review
- Article
- Article
- Dietary Terpenoids in Advancing Biofilm-Mediated Cancer Prevention: Antibiofilm Cascade, Molecular Crosstalk, and Nano-Facilitated Functional Delivery.Cell biochemistry and function · 2026Review
- Article
- Targeting tumor-associated bacteria in digestive system cancers: carcinogenic mechanisms and nano-regulate platform design.Journal of nanobiotechnology · 2026Review
- Omics-based decoding of molecular and metabolic crosstalk in the skin barrier ecosystem.Cell death and differentiation · 2026Review
- Candida albicans hyphae modulate Staphylococcus aureus cell-free supernatant during dual biofilm growth to drive molecular signatures of oral dysplasia.Medical microbiology and immunology · 2026Article
- Targeting Peptostreptococcus anaerobius with an Iron-Based Nanozyme Reverses Ferroptosis Resistance and Enhances Antitumor Immunity in Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Harnessing the microbiome for cancer therapy.Nature reviews. Microbiology · 2026Review
- Research advances in the role of circulating microorganisms in gastrointestinal tumors (Review).Molecular and clinical oncology · 2026Review
- Development of bacterial sonosensitizer hybrid systems to enhance cancer sono-immunotherapy.Acta pharmaceutica Sinica. B · 2026Article
152 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cancer cells originate from a series of acquired genetic mutations that can drive their uncontrolled cell proliferation and immune evasion. Environmental factors, including the microorganisms that colonize the human body, can shift the metabolism, growth pattern and function of neoplastic cells and shape the tumour microenvironment. Dysbiosis of the gut microbiome is now recognized as a hallmark of cancer by the scientific community. However, only a few microorganisms have been identified that directly initiate tumorigenesis or skew the immune system to generate a tumour-permissive milieu. Over the past two decades, research on the human microbiome and its functionalities within and across individuals has revealed microbiota-focused strategies for health and disease. Here, we review the evolving understanding of the mechanisms by which the microbiota acts in cancer initiation, promotion and progression. We explore the roles of bacteria in gastrointestinal tract malignancies and cancers of the lung, breast and prostate. Finally, we discuss the promises and limitations of targeting or harnessing bacteria in personalized cancer prevention, diagnostics and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.